83846-64-4

Basic information

• Product Name: 2-(2-iminothiazolidin-3-yl)-1-(3-nitrophenyl)ethan-1-one
• Synonyms: 2-(2-iminothiazolidin-3-yl)-1-(3-nitrophenyl)ethan-1-one;2-(2-Imino-3-thiazolidinyl)-1-(3-nitrophenyl)ethanone;Einecs 281-041-3
• CAS NO: 83846-64-4
• Molecular Formula: C₁₁H₁₁N₃O₃S
• Molecular Weight: 265.28834
• EINECS: 281-041-3
• Mol File: 83846-64-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 403.3°C at 760 mmHg
• Flash Point: 197.7°C
• Appearance: /
• Density: 1.49g/cm³
• Vapor Pressure: 1.03E-06mmHg at 25°C
• Refractive Index: 1.696
• CAS DataBase Reference: 2-(2-iminothiazolidin-3-yl)-1-(3-nitrophenyl)ethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-iminothiazolidin-3-yl)-1-(3-nitrophenyl)ethan-1-one(83846-64-4)
• EPA Substance Registry System: 2-(2-iminothiazolidin-3-yl)-1-(3-nitrophenyl)ethan-1-one(83846-64-4)

Safety Data

• Hazardous Substances Data: 83846-64-4(Hazardous Substances Data)

Usage

Class

Thiazolidines, heterocyclic compounds with sulfur and nitrogen atoms in their ring structure

Structure

Contains a thiazolidine ring with an imine group and a nitrophenyl group

Biological Activity

Has potential for biological activity due to the presence of the nitrophenyl group

Uses

Commonly used as a precursor or intermediate in organic synthesis

Value

Acts as a valuable building block for the development of pharmaceuticals and other bioactive compounds

InChI:InChI=1/C11H11N3O3S/c12-11-13(4-5-18-11)7-10(15)8-2-1-3-9(6-8)14(16)17/h1-3,6,12H,4-5,7H2/b12-11-

Upstream product

• 96-50-4 2-thiazolylamine 
• 2227-64-7 3'-nitro-2-bromoacetophenone 
• 1779-81-3 4,5-Dihydro-thiazol-2-ylamin 

Downstream Products

• 82191-15-9 C₁₁H₁₃N₃O₃S 
• 6646-49-7 l-6-(m-nitrophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole 
• 6649-52-1 2-(2-acetylimino-thiazolidin-3-yl)-1-(3-nitro-phenyl)-ethanone 

Relevant articles and documents

ANTHELMINTIC IMIDAZOL-THIAZOLE DERIVATES

The present invention relates to the novel anthelmintic compound tetrahydro-furan-2- carboxylic acid-[3-(2,3,5,6-tetrahydro-imidazo[2,1-b]thiazol-6-yl)-phenyl]-amide and the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, as well as pharmaceutical compositions comprising said novel compound, processes for preparing said compound and compositions, and the use thereof as a medicine, in particular in treatment, control and prevention of endo- and ectoparasite infections in warm-blooded animals.